Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism

Keyphrases

• 7-nitroindazole 100%
• Acid Gel 42%
• Anxiety-like Behavior 28%
• Autism Mouse Model 100%
• Autism Spectrum Disorder 71%
• Behavioral Deficits 14%
• Behavioral Tests 14%
• Clinical Translation 14%
• CNTNAP2 14%
• Drug System 14%
• Extended Release 100%
• Gel Formulation 100%
• In(III) 14%
• Intraperitoneal Injection 14%
• Memory Interaction 14%
• Mutant Mice 28%
• Mutant Mouse Models 14%
• Neurodevelopmental Disorders 14%
• Neuronal Nitric Oxide Synthase Inhibitor 14%
• New Preparations 14%
• Nitric Oxide Level 14%
• Nitrosative Stress 14%
• Plasma Parameters 14%
• Protein S-nitrosylation 14%
• Rational Design 14%
• Repetitive Behavior 14%
• Ricinoleic Acid 42%
• Sebacic Acid 42%
• SHANK3 100%
• Slow Release 14%
• Social Interaction 14%
• Social Interaction Anxiety 14%
• Social Interaction Behavior 14%
• Therapeutic Effect 14%
• Tyrosine 14%

Pharmacology, Toxicology and Pharmaceutical Science

• 3 Nitrotyrosine 33%
• 7 Nitroindazole 100%
• Diseases 33%
• Drug System 33%
• Intraperitoneal Injection 33%
• Mouse Model 100%
• Mouse Mutant 100%
• Neuronal Nitric Oxide Synthase 33%
• Nitric Oxide 33%
• Nitric Oxide Synthase Inhibitor 33%
• Protein S 33%
• Ricinoleic Acid 100%
• Sebacic Acid 100%
• Therapeutic Effect 33%

Neuroscience

• 7-Nitroindazole 100%
• Autism 100%
• Behavior (Neuroscience) 100%
• Behavioral Test 20%
• Blood Plasma 40%
• Compulsive Behavior 20%
• Intraperitoneal Injection 20%
• Neurodevelopmental Disorder 20%
• Neuronal Nitric Oxide Synthase 20%
• Nitric Oxide 20%
• Nitrosative Stress 20%
• Nitrotyrosine 20%
• Pervasive Developmental Disorder 100%
• Protein S 20%
• Ricinoleic Acid 60%
• Social Interaction 40%